Wall St. climbs, led by energy, healthcare; Nasdaq 100 hits 15-year high
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Valeant Pharma (VRX) Issues Dear Doctor Letter; Philidor Issues Release - Evercore ISI
November 2, 2015 9:04 PM ESTEvercore ISI analyst Umer Raffat noted two new developments in the Valeant Pharma (NYSE: VRX) saga. First the company sent a dear doctor letter to dermatologists and separately, Philidor issued a press release.
Raffat highlighted the following from the letter:
For... MoreDead Cat Bounce, Or is a Sustainable Relief Rally in Store for Valeant (VRX)?
November 2, 2015 3:17 PM ESTCitron Research founder Andrew Left's decision to step back from publishing incremental negative research on Valeant (NYSE: VRX) does absolutely nothing to change the fact that there are things we simply don't know about the company's financials, however it does temporarily remove the threat of death by 1000 tweets. This could open the door for analysts who had been supportive of the company... More
UBS Reiterates Buy on AbbVie (ABBV) Following Conference Call
November 2, 2015 9:58 AM ESTUBS reiterated a Buy rating and $78.00 price target on Abbvie (NYSE: ABBV) following the company's conference call. Management assumes no biosimiliars before 2022, and low mid-single digit annual price increases. On Humira biosimilar, management believes US biosimilars will likely infringe its dosing patents as they have to demonstrate efficacy at equal dosing.
Analyst... More
